The primary objective of this study is to investigate the hemoglobin change and association between hemoglobin change and readmissions due to heart failure, and all-cause death in patients with heart failure treated with dapagliflozin or placebo.
Study Description Brief Summary: The primary objective of this study is to investigate the hemoglobin change and association between hemoglobin change and readmissions due to heart failure, and all-cause death in patients with heart failure treated with dapagliflozin or placebo. Detailed Description: Heart failure is one of the most serious health concerns in the world, and it also remains the most common reason for hospitalization in older individuals. In patients with heart failure, anemia is associated with an increased risk of hospitalization and all-cause mortality. The DAPA-HF trial demonstrated that dapagliflozin was able to reduce the risk of worsening heart failure (HF) events and cardiovascular death comparing to placebo in patients with reduced ejection fraction on top of standard of care. This is an investigator-initiated, interventional, prospective, double-blind study. The primary objective is to investigate whether anemia correction is one of the prerequisites and determinants related to the beneficial effects of dapagliflozin in patients with heart failure. Impact of dapagliflozin treatment on hemoglobin level, heart failure-related readmission and all-cause death will be observed in comparison with placebo in heart failure patients receiving guideline recommended standard therapy during the 3months, 6 months and 1 year follow up.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
1,990
Participants will receive dapagliflozin 10 mg once daily
Participants will receive placebo 10 mg once daily
Xiangtan Central Hospital
Xiangtan, Hunan, China
RECRUITINGComposite number of hospital admissions for Heart Failure (HF) and all-cause death
Total number of deaths and heart failure hospitalizations in one year
Time frame: 1 year
Change in the Kansas City Cardiomyopathy Questionnaire (KCCQ) score
The Kansas City Cardiomyopathy Questionnaire (KCCQ) is a 23-item, self-administered instrument that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life. Scores are transformed to a range of 0-100, in which higher scores reflect better health status.
Time frame: Baselin, 3 months, 6 months, and 1 year
Change in 6-minute walk distance (6MWD)
This test measures the distance that a patient can quickly walk on a flat, hard surface in a period of 6 minutes.
Time frame: Baselin, 3 months, 6 months, and 1 year
Change in hemoglobin
g/L
Time frame: Baselin, 3 months, 6 months, and 1 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.